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The Cardiff Acne Disability Index (CADI) is a questionnaire designed to measure
the quality of life of teenagers and young adults with acne. It has been used clin-
ically and within therapeutic research globally. This review aims to appraise all
published data regarding the clinical and research experience of the CADI, its
psychometric properties and validation, from its publication in 1992 until
September 2020, in a single reference source. A literature search was conducted
using MEDLINE via Ovid, PubMed, EBSCOhost, Web of Science and Scopus. All
full articles in the English language were included. A total of 96 clinical studies
were identified and analysed. The CADI has been used in 44 different countries,
including four multinational studies, and has validated translations in 25 lan-
guages. Overall, 29 therapeutic interventions have used the CADI, demonstrating
its responsiveness to change. The reliability of the CADI has been assessed in 14
studies through test–retest and internal consistency studies. In total, 57 studies
have demonstrated aspects of its validity through correlation to other measures,
and five studies have investigated the dimensionality of the CADI. There is evi-
dence of high internal consistency, test–retest reliability, responsiveness to change
and significant correlation with other objective measures. The minimal clinically
important difference and validated score meaning bands have not yet been
reported. This information is needed to improve the interpretability of CADI
scores for clinical use and in research. The authors of the CADI have also
rephrased Question 2 of the measure to ensure inclusivity.
What is already known about this topic?
• Acne significantly impacts quality of life in patients.
• There are several skin-specific and acne-specific instruments used in day-to-day
practice and research.
• The validation and other measurement properties of the Cardiff Acne Disability
Index (CADI) have not been easily accessible.
What does this study add?
• The CADI has been extensively used and is a reliable and valid tool.
• There is a need to develop validated CADI score bands and calculate the minimal
clinically important difference.
• The CADI authors have rephrased Question 2 to ensure that the wording is inclu-
sive.
• There is inconsistent reporting of CADI data and a need for guidelines when
reporting and publishing quality-of-life data.
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Introduction
Acne, with an estimated global prevalence of 938%, is an
inflammatory condition primarily affecting the face and upper
back.1 Patients are generally treated in primary care; however,
those with severe disease or whose lives are adversely affected
are often referred to secondary care where they frequently
receive isotretinoin. Acne is most common during adolescence
with an estimated prevalence of 35% to almost 100% at any
one point.1
Adolescence is a particularly challenging period owing to
the significant biopsychosocial changes associated with indi-
viduals undergoing puberty, establishing relationships, devel-
oping persona and exploring their self-image within the adult
world. There is a great need for clinicians to fully understand
the extent of a patient’s quality-of-life (QoL) impairment in
order to inform treatment decisions. The Acne Disability Index
(ADI),2 from which the Cardiff Acne Disability Index (CADI)
was developed, was the first to measure acne-specific QoL. As
the ADI has never been used, to our knowledge, this review
focuses on the CADI.
The CADI has been used worldwide in many settings. How-
ever, valuable information regarding its clinical use and psy-
chometric properties is scattered across publications and there
has been no previous attempt to collate and appraise this pub-
lished data. It may be useful for researchers and clinicians
who wish to assess the QoL impact of acne to have ready
access to a one-stop source of all the known literature. This
review aims to collate and consolidate the data, from the
inception of the CADI in 19923 to 2020, as a one-stop refer-
ence source. This review also aims to highlight both strengths
and weaknesses of the CADI, providing a transparent reference
source while also pointing to areas requiring further validation
and identifying potential limitations of the CADI.
The Cardiff Acne Disability Index
The CADI,3 developed in 1992 by Motley and Finlay, is a short
questionnaire for use in teenagers and young adults with acne.
The CADI consists of five items with each question answered on
a 4-point Likert scale, scored from 0 to 3, resulting in a score
range of 0 to 15. A higher score represents greater QoL impair-
ment. Questions are based on the impact experienced over the
previous month. Questions 1 and 2 assess the psychological and
social consequences, Question 3 focuses on truncal acne, Ques-
tion 4 addresses the patient’s psychological state and Question 5
asks for the patient’s assessment of their acne severity. The ques-




A literature search was conducted from May to September
2020 using MEDLINE via Ovid, PubMed, EBSCOhost, Web of
Science and Scopus to identify all studies that used the CADI
from 1992 until September 2020. The search terms used in
each database were ‘Cardiff Acne Disability Index’ or ‘CADI’
and ‘acne’. Furthermore, all citations on Google Scholar of the
original 1992 publication were reviewed to identify other
studies and ensure none had been missed. Although this is not
a systematic review, PRISMA guidelines were used in part to
improve the robustness of this study. The inclusion criteria
were full-text articles that were written in English. Publications
only available as abstracts were excluded; however, citations
were checked for further relevant studies. All articles that ful-
filled the inclusion criteria were reviewed to identify clinical
and psychometric aspects of the CADI. Y.T.A. screened the
records and extracted the data. However, any ambiguity was
discussed and resolved between all other coauthors. Data were
recorded on Excel (Microsoft, Redmond, WA, USA) for cate-
gorization and information analysis. The research process is
shown in Figure S1 (see Supporting Information).
Data extraction
The psychometric data extracted included the following:
dimensionality and factor structure, test–retest reliability,
internal consistency reliability, validation against other mea-
sures, sensitivity to change, specificity compared with nonacne
populations, translations, cross-cultural adaptations and any
statistical test used. Furthermore, we extracted data on the
interpretability and clinical meaningfulness of the CADI.
The clinical information extracted included the following:
the primary aim of the study, study design and setting, coun-
try, language, therapeutic intervention, patient ages, sample
size, mean/median CADI scores for both the patients and con-
trols at baseline and postintervention, and any statistical test
used. The translation certificates of the CADI on the Cardiff
University Dermatology Quality of Life website were also anal-
ysed.4 All data were cross-checked with the original articles to
ensure accuracy.
Results
A total of 96 publications fulfilled the inclusion criteria. How-
ever, three of these studies used the CADI without reporting
data.5–7 Studies using the CADI were published in > 65 jour-
nals, most frequently in the Journal of the European Academy of Der-
matology and Venerology (eight articles) and in Dermatology (six
articles).
Psychometric data
Dimensionality and factor structure
A measure is unidimensional if there is one latent variable
between the separate items.8 Five studies9–13 analysed the
dimensionality of the CADI through factor analysis. Four of
these reported the CADI to have two factors9–11,13 (two of
which identified the same two factors)9,13 and one study
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reported the CADI to have one factor (Table S1; see Support-
ing Information).12 The two studies9,13 reported that the first
dimension comprised three items addressing emotional well-
being and the second dimension comprised the two items
addressing the social impact of acne.
Test–retest and internal consistency reliability
Test–retest reliability ensures that a scale has a low random
measurement error. If the acne severity has not changed over
time, CADI scores should not change.14,15 The test–retest relia-
bility of the CADI was assessed in six studies. Two studies
reported Spearman’s rank correlation (rs = 09816 and rs =
080);17 two studies reported Pearson’s correlation
(r = 04018 and r = 090).19 Four studies9,17,19,20 showed
intraclass correlation coefficients (ICCs) ranging from 07817
to 097,20 demonstrating high test–retest reliability (Table 1).
As the level of measurement of such data is ordinal, it would
be more appropriate to employ Spearman’s rank correlation
coefficient (rs) rather than Pearson’s correlation. It would also
be more appropriate to use ICC to test the level of agreement
between test 1 (T1) and test 2 (T2), weighing the difference
between T1 and T2 for each patient.
Overall, 12 studies reported internal consistency of the
CADI using Cronbach’s a.9,10,12,13,16,17,19–24 Values ranged
from a = 07024 to a = 09016 indicating good internal con-
sistency. The item total score correlation was reported in five
studies3,10,13,22,23 with a Spearman’s rank correlation ranging
from rs = 06023 to rs = 081,22 demonstrating strong correla-
tion between CADI items (Table 1). Four of 14 studies report-
ing either test–retest or internal consistency reliability used a
parametric test, assuming normal data distribution.
Validation against other measures
A total of 57 studies in 26 countries described CADI usage in
parallel with other closely related measures, allowing assess-
ment of construct validity of convergent type. Few studies also
described using more distantly related measures, allowing
divergent validity to be assessed (Table S2; see Supporting
Information). The most frequently reported comparator instru-
ments were the Dermatology Life Quality Index (DLQI) (con-
vergent validity,25 12 studies), the Global Acne Grading
System (GAGS) (convergent validity,26 12 studies) and the
Children’s Dermatology Life Quality Index (CDLQI) (conver-
gent validity,27 five studies). The DLQI is the most commonly
used dermatology-specific QoL measure that has been exten-
sively validated.14 In total, 12 studies examined the correlation
between CADI and DLQI scores; most demonstrated a good
positive correlation with Spearman’s rank correlation ranging
from rs = 05817 to rs = 08810 (Table S2; see Supporting
Information). Overall, 11 of 57 studies reported using para-
metric tests when comparing the CADI with other measures,
inappropriately assuming normality.
Many studies correlated the CADI with the clinicians’ evalu-
ation of acne severity using a range of clinical grading
systems, with the majority showing significant correlation
(Table S2; see Supporting Information).
Sensitivity to change
A total of 29 publications have demonstrated the sensitivity of
the CADI to change following intervention (Tables 2, 3 and
4). These studies were carried out in 22 counties, including
four multinational trials, the largest of which was conducted
across 15 countries.28 Patient numbers ranged from 10 to
3746.29,30 The reported mean decrease in CADI scores follow-
ing a variety of interventions ranged from 15 to 74.31,32 All
studies demonstrated an improvement in CADI scores follow-
ing intervention. One study7 did not report CADI data. Despite
many studies reporting statistically significant improvement in
CADI scores, it is not possible to directly interpret these score
changes based on their clinical significance as the minimal
clinically important difference (MCID) for CADI is not yet
known.
Specificity compared with nonacne populations
A prospective UK study16 reported the mean CADI score to be
significantly higher in patients with acne (mean 631) com-
pared with healthy volunteers (198), confirming high speci-
ficity for acne.
However, a retrospective Shanghai study by Wang et al.33
demonstrated a mean CADI score of 785 in patients with acne
(n = 1037) vs. 537 in healthy volunteers (n = 1046). How-
ever, the method of acne assessment was not specified. A
study by Mojica et al.24 in the Philippines conducted in pupils
in high school (aged 11 to 18 years), found that pupils with
acne scored around one point higher than those without acne.
Interpretability and clinical meaningfulness of the scores
The MCID of a measure is the smallest change in outcome that
would be considered beneficial by the patient. Knowledge of
the MCID may help clinicians interpret scores when making
clinical decisions.34,35 The MCID for CADI has not yet been
calculated and there is no validated score banding system to
provide further meaning to the scores. However, in 25 stud-
ies, unvalidated score descriptor bands were used to interpret
data (Table S3; see Supporting Information). These unvali-
dated descriptors were first introduced in 2009 and since then
they have been used in many studies.
Descriptive and clinical studies
Translations, cross-cultural adaptations and use in other
countries
Often a literal translation of a measure does not account for
linguistic, cultural and health behaviour differences.36,37
Cross-cultural adaptation aims to bridge this gap through
adopting rigorous methodology to ensure that a measure
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Table 1 Test–retest and internal consistency reliability studies
Reference Year Setting Country Sample size Test–retest Internal consistency Comment
Aghaei et al.13 2006 Hospital
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Motley and Finlay3 1992 Hospital
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Questions 1 and 5
(continued)
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retains its conceptual, experiential and semantic meaning in a
different language, culture and country.36,38 Figure 1 summa-
rizes the internationally recommended translation and cross-
cultural adaptation process.38 This includes independent for-
ward and back translation, reconciliation and cognitive
debriefing, which involves ensuring face validity.
The CADI has undergone linguistic validation in 25 lan-
guages (Table S4; see Supporting Information). Nine studies
reported cross-cultural adaptation and subsequent validation
in Cantonese, Filipino, French, Hindi, Korean, Moroccan Ara-
bic, Persian, Portuguese and Serbian (Table S5; see Support-
ing Information). A study that reported cross-cultural
adaptation in Ukrainian was otherwise excluded from this
review as it was not in English.39 The CADI has been used
in 44 countries (Table S6; see Supporting Information) and
in four multinational studies (one phase IV,30 one epidemio-
logical,40 one observational28 and one randomized therapeu-
tic phase III study)41 (Supplementary Table 7; see Supporting
Information). These took place in 15 countries across six
continents.
Topical drug interventions
The CADI has been used in 13 studies30,31,41–51 describing
pharmacological topical interventions (Table 2). The studies
investigated the use of topical nadifloxacin and benzoyl perox-
ide, clindamycin and benzoyl peroxide, combined retinalde-
hyde and glycolic acid cream, adapalene and benzoyl
peroxide, erythromycin and zinc acetate and several dermo-
cosmetic products. The pretreatment and post-treatment CADI
scores were reported in 10 studies.30,31,42,43,45–47,49–51 One
study48 reported the percentage improvement and two studies
gave a descriptive account of QoL improvement.41,44 All 14
studies depicted improvement in CADI scores following
intervention; however statistical significance was not always
reported.
Systemic drug interventions
The CADI has been used in seven studies3,7,52–56 that involved
systemic pharmacological interventions (Table 3). The sys-
temic interventions included the following: isotretinoin, azi-
thromycin, tetracycline, metformin and ‘Perfact’ face tablets.
The CADI scores were reported before and after treatment
showing statistically significant improvement in five studies.
One study54 gave a descriptive account of improvement and
another study7 did not report CADI data.
Other therapeutic interventions
Three studies57–59 reported the outcome of nonpharmacologi-
cal interventions with an educational focus (Table 4). One
study compared the use of daily text-message reminders and
patient information leaflets alongside the application of ben-
zoyl peroxide, in comparison with standard patient instruc-
tions.57 Another study focused on the outcome of text-
message reminders for adherence to treatment.58 Both studies
reported significant improvement in CADI scores following
intervention, with the greatest improvement in the text-
message group. Additionally, one study reported the impact of
patient education alongside the use of a mobile application on
the enhancement of treatment outcome.59
Four studies60–63 reported using phototherapy in treating
acne. Two studies reported CADI scores showing a significant
improvement following intervention and two gave descriptive
accounts of improvement in CADI score; however, P-values
were not always reported. One study32 describing the use of
bone marrow stem cells to treat atrophic acne scars showed a
Table 1 (continued)
Reference Year Setting Country Sample size Test–retest Internal consistency Comment










Salek et al.16 1996 Hospital
outpatients
UK 70 Spearman rank
correlation
coefficient: rs =





Tan et al.18 2012 Clinic France and
Quebec
14 Pearson’s correlation
coefficient: r = 040
Not conducted




CADI, Cardiff Acne Disability Index; ICC, intraclass correlation coefficient; OPD, outpatients department. Where reported, 95% confidence
intervals (CIs) and P-values have been displayed.
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length Mean CADI before Mean CADI after Comments
Bettoli et al.30 2019 3746 Cosmetic emulsion 2–3 months
treatment
50, SD  30
(range = 0–15)


















baseline: P < 001
Dreno et al.41 2007 128 Combined 01%
retinaldehyde/ 6%
glycolic acid cream














cream: 396, SD 
324; P < 001
Group difference: P
< 001
Gollnick et al.43 2015 5131 Adapalene 01% and
benzoyl peroxide
25% topical gel
9 months 59, SD  30 3 months: 38, SD
 27
9 months: 24, SD





Gosh and Das51 2018 37 Group A: nadifloxacin
and benzoyl
peroxide
12 weeks Baseline group A:
664, SD  04
Group A: week
12 = 088, SD 










576, SD  04
Group B: week
12 = 023, SD 






















2019 110 Niosomal benzoyl
peroxide and
clindamycin lotion
12 weeks Cases: 1189, SD
 177















2017 70 Group A: niosomal
4% erythromycin
suspension
12 weeks Group A: 85, SD
 369
Group A: 364, SD











Group B: 105, SD
 308
Group B: 287, SD
 199; P = 004
Pantoja-Villa
et al.46
2019 50 Benzoyl peroxide and
adapalene
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statistically significant improvement in CADI scores 6 months
post-treatment. One study reported a significant reduction in
CADI scores following treatment but did not report which
therapeutic intervention was used.18
Epidemiological surveys and other uses
A multinational epidemiological study conducted in 2962
patients with mild-to-moderate acne in France, Italy, Portugal
and Switzerland reported a mean CADI score of 50  30
with a range of 0–15.40 The CADI has also been used in sev-
eral studies assessing the impact of acne on QoL in nonclinical
settings. Overall, 17 studies11,17,22,23,64–76 were conducted in
schools, with reported mean CADI scores ranging from 29117
to 5865 in high schools and a mean of 1974 in primary
school children and 12173 in preadolescents. Seven stud-
ies71,77–82 were conducted in universities reporting a mean
CADI score ranging from 14777 to 37.82 A study by Cherny-
shov et al.83 reported a mean CADI score of 691 in hospital
and 381 in the community for individuals with a confirmed
acne diagnosis.
All studies used CADI in patients with acne, except for a
report of its use in Birt–Hogg–Dube syndrome,84 where the
questionnaire was modified by changing the term ‘acne’ to ‘fi-
brofolliculomas’.
Wording of Question 2
During the process of reviewing the complete CADI literature
it became apparent that the original wording of question two
is no longer appropriate in the 2020s. This review publication
provides the opportunity to announce a change in the word-
ing of one CADI question. The original wording of Question
2, addressing relationships ‘with the opposite sex’, does not
take different sexual orientations into account. We confirm
that the authors of the CADI (R.J.M. and A.Y.F.) have
rephrased Question 2 to ensure that the CADI is inclusive and
suitable for all patients. The phrase ‘relationships with mem-
bers of the opposite sex’ has been changed to ‘intimate per-
sonal relationships’. Therefore, the revised wording of
Question 2 is ‘Do you think that having acne during the last
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2 months Group A: 49, SD
 26








Group B: 47, SD
 23
Group B: 32, SD 
28 (312%)
P < 001
Tabasum et al.47 2014 48 Test group: ’Zimade
Mahusa’ a Unani
antiacne formulation




































cream gel + tonic
(full treatment
group)
Group 3: 407 Approximately 2 Group 3: 449%
improvement in
CADI
NR, not reported; QoL, quality of life. Where reported, 95% confidence intervals and P-values have been displayed.
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intimate personal relationships?’ However, this change
requires confirmation by a content validity study.
Discussion
Understanding the impact of disease allows a more holistic
and patient-centred approach to healthcare. The concept of
measuring the effect of skin disease on a patient’s QoL is
becoming increasingly accepted and integrated within routine
clinical practice and research.85,86
This review has demonstrated the extensive use of the
CADI, described as the easiest QoL scale to use in routine der-
matology practice.87 Additionally, a recent systematic review
identified the CADI to be among the top five most commonly
used instruments for measuring the impacts of acne.88 How-
ever, frequency of use is not a guide to the quality of a mea-
sure. Several studies reported choosing the CADI because of its
short completion time of around 1 min in English4 and
15 minutes in Filipino.24 However, the practicalities of a
measure must be balanced against its validity. We have col-
lated the psychometric properties of the CADI, demonstrating
aspects of its reliability and validity. It is responsive to change
and can discriminate between treatments of different effective-
ness (Tables 2–4). Although acne severity does not always
correlate with QoL impairment,3 the majority of studies
reported a correlation between CADI and clinicians’ acne grad-
ing, as an objective measure. Four studies reported the CADI
to be bidimensional with the exception of a study by Kyeong-
Han et al. that reported unidimensionality.12 This may be due
to the researchers examining the Korean translated version of
the CADI in addition to the different study population. Fur-
thermore, no studies performed confirmatory factor analysis.
There are a variety of QoL questionnaires used in acne.
These include generic measures, such as the 36-Item Short
Form Survey or EQ-5D and dermatology-specific measures,
such as DLQI, CDLQI, Skindex or Teenagers’ Quality of Life
(T-QoL), a questionnaire designed for teenagers with any skin
disease.89 In addition to the CADI, there are other acne-
specific QoL measures, including Assessment of the Psycholog-
ical and Social Effects of Acne (APSEA), Acne-specific Quality
of life questionnaire (Acne-QoL), Acne-Q4, Acne Quality of
Life Scale (AQOL), Acne Quality of Life Index (Acne-QOLI)
and Acne Symptom and Impact Scale (ASIS).90 The validation
of these measures has been summarized.90
Despite the extensive validation of the CADI, certain psy-
chometric properties require further investigation. The use of
arbitrary unvalidated score bands by investigators highlights
the need for developing validated score meaning bands. The
anchor-based approach91 might be the most suitable for the
CADI as it is a short, simple questionnaire.92 There is also no
MCID reported for the CADI, and users of the CADI should be
aware of this when interpreting score change in order to
inform routine clinical decision making and when carrying
out research.93
Several studies have attempted to correlate CADI data with a
range of demographic items such as sex, education level and
socioeconomic class. Correlation results were varied and
inconclusive overall. The majority of participants in these
studies were female. This may be due to the clinic-based set-
ting of most studies, and the possibility that women may be
more likely to seek treatment for their acne than men.
Although the CADI was designed for use in adolescents and
young adults with acne, this review identified that the CADI
has also been used in older age groups, both in routine prac-
tice and for therapeutic research.
There are 25 validated translations of the CADI; however,
the majority of translations, although created using a standard
process of forward and backward translations, have not under-
gone full cross-cultural adaptation. Ideally this should be con-
ducted for all translations.36,38 Several authors chose the CADI
because there was a validated version in their language. The
use of trained translators and pretesting on bilingual lay peo-
ple is recommended by guidelines to ensure optimal compre-
hension,36 and this was mostly adhered to. Studies often
Figure 1 Recommended translation and cultural adaptation process.38
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compared CADI scores between different cultures; however, as
for all QoL measures, despite cross-cultural adaptation, similar
CADI scores in different countries should not be assumed to
be directly comparable as perceptions of health and QoL are
culturally influenced.37
Patients should ideally complete QoL questionnaires alone,
as having the clinician present may influence responses. How-
ever, in one study, the CADI was read aloud to patients who
were illiterate17 and in another study, the CADI questionnaire
was administered over the phone.94 As virtual appointments
become integrated into outpatient dermatology care, it may
become routine practice for QoL questionnaires to be com-
pleted via apps or over the phone. The use of the DLQI on an
app has been validated against the paper version,95 providing
encouragement that other QoL questionnaires delivered in this
way may also be valid; however, this remains to be estab-
lished for the CADI. For future research, it would be prudent
to develop an electronic version of the CADI and test it for
psychometric equivalency to that of the paper version.
The European Academy of Dermatology and Venereology
Quality of Life Task Force has published recommendations for
the use of QoL measures generally, and specifically in acne.90
Inconsistencies within QoL reporting have been previously
identified.96 This has also occurred in the reporting of CADI
data; inappropriate unvalidated score banding has been intro-
duced and frequently used. Baseline and end-of-treatment data
values were sometimes missing and P-values not always
reported. SDs and confidence intervals were frequently omit-
ted. The CADI is an ordinal scale, but parametric tests were
sometimes applied, inappropriately assuming normality. In a
few reports it was not clear which statistical test was used.
Two studies used an incorrect score range52,53 and another
reported data outside the possible range.21 We have previously
highlighted this lack of quality assurance in the use and
reporting of QoL studies97–100 and recommend the implemen-
tation of formal guidelines and tighter requirements for pub-
lishing QoL data.96
The main limitation of this review is that only English-
language reports were included; however, several studies
using the CADI in other languages were identified. We were
not able to obtain the articles describing three studies that
used the CADI. Articles frequently had inadequate QoL report-
ing, which affected the ability to interpret data. Although
extensive searching was conducted to identify all articles, it is
possible that some may have been missed.
Conclusions
We have presented the extensive use and psychometric prop-
erties of the CADI, to act as a reference for potential users.
The CADI is a short, practical and effective measure to assess
acne-related QoL impairment. Question 2 of the CADI has
been rephrased to ensure that it is an appropriate measure for
all patients. Further investigation with regards to score mean-
ing banding and the MCID is needed to assist the
interpretation of CADI scores. Finally, validation of CADI
delivery by app or over the phone should be carried out.
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